IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC. ©2026 Investor's Business Daily, LLC. All Rights Reserved. Terms of Use Privacy Notice Accessibility About Us Reviews Site Map Your Ad Choices Advertising Contact us IBD Stock Charts IBD Stock Checkup Stock Quotes Stock Market Today The Big Picture My Stock Lists IBD Live Leaderboard SwingTrader MarketSurge IBD Digital MarketDiem The ...

公司评级与目标价 - H C Wainwright 首次覆盖 Evommune 给予买入评级 目标价为35美元 [1] 投资逻辑与催化剂 - 近期股价疲软创造了有利的风险回报比 关键催化剂为2026年的临床数据读出 [1] - 在MRGPRX2靶点领域的竞争已收窄 [1] - 2026年的积极数据可能推动估值上升并引发战略收购兴趣 [3] 公司产品管线与市场 - 公司专注于服务不足的巨大炎症和免疫学市场 战略灵活性正在改善 [1] - 公司拥有两个临床阶段资产：口服MRGPRX2抑制剂EVO-756 用于慢性自发性荨麻疹和特应性皮炎 以及IL-18抑制剂EVO-301 用于特应性皮炎和溃疡性结肠炎 [3] - 在慢性诱导性荨麻疹的早期人体概念验证数据 支持其对慢性自发性荨麻疹的推断 [2] 公司竞争优势 - 早期研究显示其产品具有清晰的安全性特征 这是一个重要的差异化优势 特别是考虑到其他口服MRGPRX2项目近期因毒性问题受挫 [2] - 创始团队曾成功创立Dermira 该公司以11亿美元出售给礼来 并曾将lebrikizumab和Qbrexza推进为商业化产品 [3]

SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan 13, 2026 at 4:30pm PT / 7:30pm ET. A live webcast of the presentation will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/presen ...

After turning in a strong performance to kick off the first full trading week of the new year, stocks saw further upside during trading on Tuesday. With the continued upward move, the Dow and the S&P 500 reached new record closing highs.The major averages ended the day just off their highs of the session. The Dow jumped 484.90 points or 1.0 percent to 49,462.08, the Nasdaq climbed 151.35 points or 0.7 percent to 23,547.17 and the S&P 500 rose 42.77 points or 0.6 percent to 6,944.82.The Dow benefitted from ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

诉讼概述 - 律师事务所Levi & Korsinsky, LLP通知Skye Bioscience, Inc. (NASDAQ: SKYE)的投资者，有一项集体诉讼证券诉讼正在进行 [1] - 该诉讼旨在为在2024年11月4日至2025年10月3日期间因涉嫌证券欺诈而遭受不利影响的投资者挽回损失 [1] - 投资者若在此期间遭受损失，需在2026年1月16日前请求法院指定其为首席原告 [3] 指控内容 - 诉讼指控被告作出了虚假陈述和/或隐瞒了以下事实：公司的主要候选产品nimacimab的效果不如被告向投资者所宣称的那样有效 [2] - 因此，nimacimab的临床、监管和商业前景被夸大 [2] - 结果导致，被告在相关时间内的公开陈述存在重大虚假和误导性 [2] 投资者参与方式 - 投资者可通过提供的链接获取更多信息并与团队取得联系 [1] - 投资者也可通过电子邮件jlevi@levikorsinsky.com或电话(212) 363-7500联系Joseph E. Levi, Esq. [1] - 作为集体成员，投资者可能有权获得补偿，且无需支付任何自付费用，参与没有成本或义务 [3] 律师事务所背景 - Levi & Korsinsky律师事务所在过去20年里，已为受损股东追回数亿美元（hundreds of millions of dollars），并建立了赢得高风险案件的记录 [4] - 该事务所在代表投资者处理复杂证券诉讼方面拥有丰富专业知识，拥有超过70名员工组成的团队为客户服务 [4] - 连续七年，Levi & Korsinsky在ISS Securities Class Action Services的Top 50报告中被评为美国顶级证券诉讼律师事务所之一 [4]

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces the launch of a public offering of common shares in the capital of the Company (the “Common Shares”) and, in lieu of Common Shares to investors that so choose, pre-funded warrants (the “Pre-Funded Warrants”) to purchase Common Shares, for aggregate gross proceeds of US$100 million (the “Offering”). In connection with the Offering, the Company intends to grant to th ...

PresentationPlease note that today's conference is being recorded. I will now hand the conference over to your speaker host, Will Roberts, Head of Communications. Please go ahead.Good day and thank you for standing by. Welcome to the Aclaris ATI-052 Clinical Trial Update Conference Call. [Operator Instructions]William RobertsSenior VP of Corporate Communications & Investor Relations Thank you, Olivia, and good morning, everyone, and welcome to the Aclaris Therapeutics conference call to review the positive ...

Eli Lilly is in advanced talks to buy Ventyx Biosciences for over $1 billion, the Wall Street Journal reported on Tuesday, citing people familiar with the matter. ...

The more-than-$1 billion deal could come imminently. ...